Australia Markets open in 3 hrs 16 mins

Actinogen Medical share price crashes 67% lower on Alzheimer’s study results

James Mickleboro
production of drugs in the lab

One of the worst performers on the Australian share market on Tuesday has been the Actinogen Medical Ltd (ASX: ACW) share price.

In morning trade the Alzheimer’s-focused drug development company’s shares are down 67% to 1.6 cents.

Why has the Actinogen Medical share price crashed lower today?

Investors have been hitting the sell button this morning after Actinogen Medical released the results of its XanADu phase II clinical trial of 10mg Xanamem in patients with mild dementia due to Alzheimer’s disease.

According to the release, the XanADu trial established that a 10mg daily dose of Xanamem is safe and has the ability to effectively inhibit cortisol production, as demonstrated by the expected increase in related hormones, including adrenocorticotropic hormone (ACTH).

However, it did not demonstrate adequate efficacy in improving cognition in mild Alzheimer’s disease. Disappointingly, the primary and secondary endpoint measures did not demonstrate statistical differences between Xanamem 10mg and placebo.

What now?

It isn’t necessarily the end of the road just yet. Management advised that further analysis of the trial data is underway in the hope of exploring trends that could identify any specific cognitive domains in which positive trends may be evident.

It also suggested that higher doses of Xanamem and longer treatment durations may be necessary to effectively demonstrate its potential to improve cognition in Alzheimer’s disease.

Studies using 20mg and 30mg doses are underway and results are expected to be announced by the end of June. After which, management will use the data to refine Xanamem’s ongoing clinical development program.

Despite the disappointing results, the company’s CEO, Dr Bill Ketelbey, was encouraged by the trial.

He said: “These XanADu results are certainly encouraging. While 10mg Xanamem was not shown to be a clinically effective dose in Alzheimer’s disease, the safety and pharmacodynamic effects observed show potential that higher doses and a longer treatment duration of Xanamem may be efficacious.”

Also in the news today in the pharmaceutical industry is Mayne Pharma Group Ltd (ASX: MYX). The Mayne Pharma share price has dropped 1% lower after analysts at UBS held firm with their neutral rating but cut the price target on its shares to 73 cents after revising down margins for its generics segment.

Elsewhere, the CSL Limited (ASX: CSL) share price has pushed 1% higher despite there being no news out of the biotech giant.

Finally, here's a small cap healthcare share which has been tipped for very big things in the future.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click here to learn more on how you can profit from the coming cannabis boom.

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019